Indiana University Comprehensive Training in Clinical Pharmacology

描述（由申请人提供）：印第安纳州大学临床药理学培训计划在过去五年中发生了重大变化，因此它现在代表了一个更全面和前沿的培训计划。它的目的是提供一个强大的供应临床药理学培训的临床科学家，一个学科非常适合我们的 国家目前的努力，以增加新的和有效的治疗转化为临床实践。该申请旨在继续一个既定的计划，在培训成功的翻译临床医生科学家方面具有卓越的记录。在过去的资助期间，该计划增加了药物计量学，儿科临床药理学和个性化医学的正式培训，并通过建立印第安纳州个性化医学研究所而变得更加强大。在药物处置，药物基因组学和药物开发方面建立的卓越计划已经通过新的儿科治疗卓越中心和PREGMED（NICHD产科药理学研究网络网站）进行了更深入的教学培训。一个15人的核心教师已被选定的基础上，与临床药理学，同行评审的资金和培训成功的质量研究。该核心教师资助了癌症，心血管，艾滋病毒，胃肠道，儿科，产科和老年临床药理学的基础和临床方法的研究项目， 以及药物性肝病、药物代谢和处置、药物相互作用、药物基因组学和治疗研究中的伦理学。核心教师连同22个支持教师现在允许这个程序作为该机构的临床研究企业内的中心支柱。该计划有助于广泛的同行评审研究，并提供了关键的协同作用内的印第安纳州CTSI催化的翻译研究培训。学员参加专门组织的每周团队期刊俱乐部，以打破实验室和临床专业之间的孤岛，临床药理学和个性化医疗研讨会，以及有组织的每周教学计划，在两年的周期内全年运行。深入的教学培训现在集中在药代动力学，药物和代谢物分析，药物基因组学，药物计量学，药物开发，个性化治疗，以及产科，儿科，成人和老年临床治疗的临床试验设计。学员还可以选择参加印第安纳州大学临床研究理学硕士课程。核心教师根据他们作为临床科学家的潜力，从具有医学博士学位的候选人中选择2至3年计划的学员，PharmD、PhD或M.D./博士学位和足够的临床培训，以获得初级专业认证。自2004年首次资助以来， 1992年，合格的申请人填补了培训补助金的空缺，没有一个强大的申请人管道。我们的计划产生了稳定资助的学术医生科学家和制药行业的领导者，并继续在培训临床药理学家方面发挥突出的国家作用。

DESCRIPTION (provided by applicant): The Indiana University Training Program in Clinical Pharmacology has evolved significantly over the past five years, such that it now represents a more comprehensive and cutting edge training program. It is designed to provide a robust supply of clinician scientists trained in clinical pharmacology, a discipline ideally suited to our nation's current efforts to augment the translation of new and effective therapies into clinical practice. This application seeks to continue an established program that has a track record of excellence in training successful translational clinician scientists. The program has added formal training in pharmacometrics, pediatric clinical pharmacology and personalized medicine over the last funding period and has been made more robust by the establishment of the Indiana Institute for Personalized Medicine. The established program excellence in drug disposition, pharmacogenomics and drug development has been augmented with deeper didactic training by a new Center for Excellence in Pediatric Therapeutics and PREGMED, an NICHD Obstetric Pharmacology Research Network site. A core faculty of 15 has been selected on the basis of quality research related to clinical pharmacology, peer-reviewed funding and training success. This core faculty has funded research programs in both basic and clinical approaches to cancer, cardiovascular, HIV, gastrointestinal, pediatric, obstetric and geriatric clinical pharmacology, as well as drug-induced liver disease, drug metabolism and disposition, drug interactions, pharmacogenomics, and ethics in therapeutic research. The core faculty together with 22 supporting faculty now allow this program to serve as a central pillar within the institution's clinical research enterprise. The program contributes to a wide range of peer-reviewed research and provides critical synergies within the Indiana CTSI-catalyzed training for translational research. Trainees attend weekly team journal clubs specifically organized to break down silos between laboratories and clinical specialties, seminars in clinical pharmacology and personalized medicine, and an organized weekly didactic program that runs year round in a two year cycle. In depth didactic training now concentrates on pharmacokinetics, drugs and metabolites analysis, pharmacogenomics, pharmacometrics, drug development, individualized therapeutics, and clinical trial design in obstetric, pediatric, adult and geriatric clinical therapeutics. Trainees may also elect to participate in the Indiana University Master of Science in Clinical Investigation. The core faculty selects trainees for the 2 to 3 year program based on their potential as clinician scientists from candidates with M.D., PharmD, PhD, or M.D./ Ph.D. degrees and sufficient clinical training for primary specialty certification. Since first funded in 1992, qualified applicants have filled the training grant slots, and a robust applicant pipeline no exists. Our program has generated stably funded academic physician scientists and leaders in the pharmaceutical industry and continues to serve a prominent national role in training clinical pharmacologists.